Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Travere Therapeutics, Inc.

SG&A Trends: Merck vs. Travere Over a Decade

__timestampMerck & Co., Inc.Travere Therapeutics, Inc.
Wednesday, January 1, 20141160600000059644696
Thursday, January 1, 20151031300000079541000
Friday, January 1, 2016976200000098015000
Sunday, January 1, 20179830000000103958000
Monday, January 1, 201810102000000103654000
Tuesday, January 1, 201910615000000128951000
Wednesday, January 1, 20208955000000135799000
Friday, January 1, 20219634000000149883000
Saturday, January 1, 202210042000000220206000
Sunday, January 1, 202310504000000265542000
Loading chart...

In pursuit of knowledge

A Decade of SG&A: Merck & Co., Inc. vs. Travere Therapeutics, Inc.

In the ever-evolving pharmaceutical industry, operational efficiency is key. Over the past decade, Merck & Co., Inc. and Travere Therapeutics, Inc. have showcased contrasting trends in their Selling, General, and Administrative (SG&A) expenses. Merck, a giant in the industry, consistently reported SG&A expenses averaging around $10 billion annually, with a notable peak in 2014. In contrast, Travere Therapeutics, a smaller player, saw its SG&A expenses grow by over 340% from 2014 to 2023, reflecting its aggressive expansion strategy.

While Merck's expenses remained relatively stable, Travere's increase highlights its commitment to growth and market penetration. This comparison underscores the diverse strategies employed by pharmaceutical companies to manage operational costs while striving for innovation and market leadership. As the industry continues to evolve, these insights provide a glimpse into the financial strategies shaping the future of healthcare.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025